Related Experiment Video
Updated: Sep 26, 2025
Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
Published on: March 30, 2022
Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
Alexander J Bolt1, Linh D Do1, Maryam Raeeszadeh-Sarmazdeh2
1Department of Chemical & Materials Engineering, University of Nevada, Reno.
Abstract:
Matrix metalloproteinases (MMPs) belong to the family of metzincin proteases with central roles in extracellular matrix (ECM) degradation and remodeling, as well as interactions with several growth factors and cytokines. Overexpression of specific MMPs is responsible in several diseases such as cancer, neurodegenerative diseases, and cardiovascular disease. MMPs have been the center of attention recently as targets to develop therapeutics that can treat diseases correlated to MMP overexpression. To study the MMP mechanism in solution, more facile and robust recombinant protein expression and purification methods are needed for the production of active, soluble MMPs. However, the catalytic domain of most MMPs cannot be expressed in Escherichia coli (E. coli) in soluble form due to lack of posttranslational machinery, whereas mammalian expression systems are usually costly and have lower yields. MMP inclusion bodies must undergo the tedious and laborious process of extensive purification and refolding, significantly reducing the yield of MMPs in native conformation. This paper presents a protocol using Rosetta2(DE3)pLysS (hereafter referred to as R2DP) cells to produce matrix metalloproteinase-3 catalytic domain (MMP-3cd), which contains an N-terminal His-tag followed by pro-domain (Hisx6-pro-MMP-3cd) for use in affinity purification. R2DP cells enhance the expression of eukaryotic proteins through a chloramphenicol-resistant plasmid containing codons normally rare in bacterial expression systems. Compared to the traditional cell line of choice for recombinant protein expression, BL21(DE3), purification using this new strain improved the yield of purified Hisx6-pro-MMP-3cd. Upon activation and desalting, the pro domain is cleaved along with the N-terminal His-tag, providing active MMP-3cd for immediate use in countless in vitro applications. This method does not require expensive equipment or complex fusion proteins and describes rapid production of recombinant human MMPs in bacteria.
Insights
Researchers developed a new method for producing active matrix metalloproteinase-3 catalytic domain (MMP-3cd) in bacteria. This improved bacterial expression and purification yields active MMP-3cd for disease research and therapeutic development.
Area of Science:
- Biochemistry
- Molecular Biology
- Protein Expression
Background:
- Matrix metalloproteinases (MMPs) are crucial for extracellular matrix remodeling and implicated in diseases like cancer.
- Current methods for producing active MMPs, especially the catalytic domain, face challenges with solubility and yield in bacterial systems.
- Mammalian expression systems are costly and yield less protein, while bacterial expression often results in insoluble inclusion bodies requiring extensive refolding.
Purpose of the Study:
- To develop a facile and robust protocol for expressing and purifying active matrix metalloproteinase-3 catalytic domain (MMP-3cd) in bacteria.
- To overcome the limitations of traditional bacterial expression systems for producing soluble and active MMPs.
- To provide a cost-effective and efficient method for obtaining active MMP-3cd for in vitro applications.
Main Methods:
- Utilized Rosetta2(DE3)pLysS (R2DP) cells, engineered to enhance eukaryotic protein expression using rare codons.
- Expressed MMP-3cd with an N-terminal His-tag and pro-domain (Hisx6-pro-MMP-3cd) for affinity purification.
- Activated the purified protein to cleave the pro-domain and His-tag, yielding active MMP-3cd.
Main Results:
- The R2DP cell system significantly improved the yield of purified Hisx6-pro-MMP-3cd compared to BL21(DE3) cells.
- The protocol successfully produced active MMP-3cd after pro-domain cleavage and desalting.
- The method demonstrated rapid production of recombinant human MMPs in bacteria without complex fusion proteins or expensive equipment.
Conclusions:
- The R2DP cell-based protocol offers an efficient and cost-effective strategy for producing active MMP-3cd in bacteria.
- This method facilitates the study of MMP mechanisms and the development of MMP-targeted therapeutics.
- The protocol is adaptable for the rapid production of other recombinant human MMPs.
